TRACKING NOVAVAX

[dothedd]

Novavax gains on continued optimism over its RSV vaccine • 2:08 PM 8/19/13

Novavax (NVAX +4.9%) gains on renewed optimism that the company may announce positive news on its Respiratory Syncytial Virus Fusion Vaccine at its annual Analyst Day on September 24.

Last week Lazard upped its price target on the shares to $11, saying the vaccine was "one of the more under-appreciated assets in the industry."

The firm thinks NVAX's drug could be more effective than its competitor, Synagis.
Additionally, Italian veterinary authorities have reported an outbreak of highly pathogenic avian influenza at a commercial poultry farm in Emilia-Romagna, an administrative region in Northern Italy.

[dothedd]

NVAX  $2.860.21(7.92%)  Novavax, Inc.8/19/2013, 2:50 PM ET

When Stanley Erck, President and Chief Executive Officer of Novavax Inc., summed up the accomplishments of his team in the second quarter of this year on August 8th, he threw an unturned card on the table in addition to his losing pair of deuces.

Novavax (NVAX) will have its first Analyst's Meeting since the rebirth of the company as a vaccine maker in the year 2005 on September 24th of this year. No one knows what that wild card might be. The mystery makes it the single biggest catalyst in the history of this stock and perhaps the biggest biotech run-up event in the waning months of summer. in Erck's own words...


And so finally, and mark your calendars, September 24 Analyst Meeting will be held. We expect to cover some important activities, including clinical development plans for our RSV maternal program, clinical development plans for RSV elderly and the possibilities for a combination respiratory vaccine, we'll talk about the timing of our RSV pediatric program, our seasonal flu program and our pandemic flu program under BARDA. Hopefully, we'll have some additional insights into the timing of the rabies Phase I trial and finally, we'll update you on any new emerging virus product development activities.


NVAX  $2.880.23(8.68%) Novavax, Inc.8/19/2013, 2:59 PM ET

[dothedd]

MACD(12,26,9) Bull Crossover Stocks (Aug. 19)

NASDAQ: NVAX (Novavax)

NASDAQ: NVAX (Novavax) has closed at $2.9, its traded Volume was 6758.17K shares, NVAX opened the Day at $2.72, it made an intraday Low of $2.69, and an intraday High of $2.9199. NVAX (Novavax) 52-week High is $2.93, 52-week Low is: $1.52, it has supports at $2.25 and $1.84, resistances at $2.93 and $3.42. NVAX’s earning is $-0.26 per share, Next quarter estimated EPS is $-0.06, current year estimated EPS is $-0.27. Its PE ratio is -11. Overall, this stock is rated BUY today.

www.ninestocks.com/2013/08/macd12269-bull-crossover-stocks-aug-19/